Vibro-Acoustography Imaging in Finding Breast Microcalcifications and Lesions in Women
NCT ID: NCT00626119
Last Updated: 2012-06-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
34 participants
OBSERVATIONAL
2001-06-30
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying how well vibro-acoustography imaging works in finding breast microcalcifications and lesions in women.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vibro-Acoustography Imaging in Diagnosing Breast Masses in Women With a Breast Mass or Breast Cancer
NCT00627614
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
NCT04799535
Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities
NCT06058650
New Technique as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer
NCT00566085
Use of Low-dose Molecular Breast Imaging for the Detection of Small Breast Lesions
NCT01285440
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To further develop a new method of in vivo imaging of the breast using vibro-acoustography (VA) imaging.
* To demonstrate and evaluate the capability of VA imaging in detecting microcalcifications and lesions inside the human breast.
OUTLINE: Participants undergo vibro-acoustography (VA) imaging of the breast using ultrasonography over 90 minutes. Participants may also undergo further imaging using clinical ultrasonography.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
No interventions assigned to this group
diseased
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meets one of the following criteria:
* Healthy participant
* Proven microcalcifications and/or lesions in the breast
* Hormone status not specified
PATIENT CHARACTERISTICS:
* Female
* Menopausal status not specified
* Not pregnant or nursing
* No condition that does not allow proper use of study imaging devices
PRIOR CONCURRENT THERAPY:
* Not specified
18 Years
85 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mayo Clinic
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mostafa Fatemi, PhD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Cancer Center
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDR0000583249
Identifier Type: REGISTRY
Identifier Source: secondary_id
729-01-0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.